reports
Abivax: 1 director
A director at Abivax sold 1,200,000 shares at 94.085EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
UPDATE ON FIXED INCOME INVESTOR MEETINGS
UPDATE ON FIXED INCOME INVESTOR MEETINGS Press release Antwerp, Oct. 23, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) references the stock exchange release dated 20 October 2025 regarding fixed income investor meetings. Following engagement with potential investors, CMB.TECH has decided not to proceed with the issue of a senior unsecured bond. The indicative terms offered under the current market conditions were less favourable compared to the other funding sources available to the Company. For further informat...
- Kristof Samoy
CMB.Tech Unscheduled 3Q25 trading update released
This morning CMB.TECH issued an update which went unnoticed due to technical issues. We presume the release has to do with the ongoing fixed income investor meetings to refinance (half of) the $1.4bn bridge loan taken out to acquire the stake in Golden Ocean. The update was limited to the publication of TCE rates and confirmed the rumoured sale of the VLCC Dalma (°2007) which resulted in a handsome $27m capital gain. The attractive rate fixtures in the 4Q25 more than make up for the shortfall in...
- Hilde Van Boxstael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
PRESS RELEASE: CMB.TECH NV announces fixed income investor meetings
PRESS RELEASE: CMB.TECH NV announces fixed income investor meetings Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) has mandated Danske Bank, DNB Carnegie, Nordea Bank and Pareto Securities to arrange a series of fixed income investor meetings commencing today, October 20, 2025. Following the investor meetings a USD denominated five-year senior unsecured bond issue may follow, subject to inter alia market conditions. The proceeds from the potential bond issue will be used for general corporate purp...
PRESS RELEASE: CMB.TECH trading update
PRESS RELEASE: CMB.TECH trading update Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) provides a market update. During Q3 and Q4 to date, CMB.TECH has continued its fleet rejuvenation strategy with the sale of two older vessels and the delivery of five newbuild vessels. Fleet update Deliveries CMB.TECH took delivery of 5 newbuilding vessels in Q3 and Q4 to date: Eco-Newcastlemaxes: Mineral Slovensko and Mineral Slovenija Chemical tanker: Bochem Santos CTV: Windcat 58 ...
- Kristof Samoy
CMB.Tech IMO Postpones Vote on Adoption of Net Zero Framework
On Friday afternoon, news broke—confirming earlier speculation on Thursday—that the IMO has postponed the vote on adopting the Net-Zero Framework by one year. The delay followed intense lobbying against the measures, led by the US and Saudi Arabia. In Friday's vote, 57 countries supported the delay (including the US, China, Panama, and Liberia), while 49 opposed (including most EU member states). The path forward for shipping emissions regulation remains unclear, with renegotiation potentially r...
- Ahmed Ben Salem
- Baptiste Lebacq
TEMN TEMENOS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
HCO HIGHCO SA
GLO GL EVENTS SA
ENI ENI S.P.A.
BAMNB KONINKLIJKE BAM GROEP NV
REP REPSOL SA
SIX2 SIXT SE
SLIGR SLIGRO FOOD GROUP N.V.
FDR FLUIDRA S.A.
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BP. BP P.L.C.
PWG PRODWAYS GROUP SA
THEP THERMADOR HOLDING SA
FAST FASTNED
ALHRS HYDROGEN REFUELING SOLUTIONS
SHEL SHELL PLC
CAN CANAL+
- Ahmed Ben Salem
- Baptiste Lebacq
TEMN TEMENOS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ALFOC FOCUS HOME INTERACTIVE SA
OSE OSE IMMUNOTHERAPEUTICS SA
HCO HIGHCO SA
GLO GL EVENTS SA
ENI ENI S.P.A.
BAMNB KONINKLIJKE BAM GROEP NV
REP REPSOL SA
SIX2 SIXT SE
SLIGR SLIGRO FOOD GROUP N.V.
FDR FLUIDRA S.A.
MAU ETABLISSEMENTS MAUREL & PROM SA
FTG111 FLATEXDEGIRO AG
BP. BP P.L.C.
PWG PRODWAYS GROUP SA
THEP THERMADOR HOLDING SA
FAST FASTNED
ALHRS HYDROGEN REFUELING SOLUTIONS
SHEL SHELL PLC
CAN CANAL+
- Jeremy Garnier
- Jeremy Garnier
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Wim Lewi
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in particip...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Res...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p
Abivax Announces Acceptance of Additional Late-Breaking Abstract from ...
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) ...
- Fehmi Ben Naamane
- Fehmi Ben Naamane
- Andreas Riemann
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod...
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax manage...
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.